McKesson second-quarter results: revenue up 8% to $111 billion
McKesson Corporation reported preliminary results for the quarter ended September 30, 2026. Consolidated revenue grew 8% to $111 billion. Earnings per diluted share (EPS) for the period were $10.44, up $1.52 from the year-ago quarter.
Key points
- Key business segments drove the 8% revenue growth.
- Quarterly financial results include costs from restructuring and corporate initiatives.
Financial results and strategic initiatives
Key business segments drove the 8% revenue growth. North American Pharmaceutical Services revenue was $91.4 billion (up 6%), Oncology & Multispecialty Services revenue was $15 billion (up 24%), and Prescription Technology Solutions revenue was $1.5 billion (up 10%). The Medical-Surgical Solutions segment grew 5% to $3.1 billion in revenue.
The company completed several strategic moves. It extended its pharmaceutical distribution partnership with CVS Health through June 2032, signed a $1.4 billion deal for a minority stake in Option Care Health, Inc., and finalized its acquisition of Precision Medicine Group, LLC.
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Impact of restructuring costs
Quarterly financial results include costs from restructuring and corporate initiatives. The Prescription Technology Solutions segment incurred $18 million in restructuring costs, while the Medical-Surgical Solutions segment recorded $42 million in net charges related to the planned separation of that business.
Outlook
Investors should monitor future company reports and quarterly materials to track how restructuring costs and the integration of Precision Medicine Group affect future financial performance.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Mckesson
A notification in your browser or on your phone when we publish about Mckesson. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
